CNBX CNBX Pharmaceuticals Inc.

OTC Pharmaceutical Preparations NV CIK: 0001343009
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

CNBX is in severe financial distress with negative stockholders' equity of -$2.6M, liabilities exceeding assets, and virtually no revenue generation. The company is burning cash with -$47.4K operating cash flow and has negligible liquid assets of $7.7K, indicating imminent solvency risk.

Strengths

  • + Minimal capital expenditure suggests no major cash drains from asset purchases
  • + Some form of continued operations despite extreme financial stress
  • + Extremely low absolute debt levels relative to industry

Risks

  • ! Negative stockholders' equity indicates technical insolvency and balance sheet impairment
  • ! Zero revenue generation with no meaningful profitability pathway visible
  • ! Severe liquidity crisis with current ratio of 0.00 and only $7.7K cash against $586.2K liabilities
  • ! Negative operating cash flow of -$47.4K indicates ongoing cash burn
  • ! No insider confidence demonstrated by absence of Form 4 filings in last 90 days
  • ! Negative ROA of -1018.8% shows extreme asset value destruction

Key Metrics to Watch

Financial Metrics

Revenue
0.0
Net Income
-113.7K
EPS (Diluted)
$0.00
Free Cash Flow
-47.4K
Total Assets
11.2K
Cash
7.7K

Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -1,018.8%
FCF Margin N/A

Balance Sheet & Liquidity

Current Ratio
0.00x
Quick Ratio
0.00x
Debt/Equity
N/A
Debt/Assets
5,251.9%
Interest Coverage
-1.38x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-22T15:04:10.339525 | Data as of: 2025-11-30 | Powered by Claude AI